

**Rocky Mountain Urological Society
2017 Annual Spring Meeting
April 7 - 8, 2017
Embassy Suites Denver Tech Center
Centennial, Colorado**

PROGAM BOOK



Scott Jennings, MD
RMUS President



Brian J. Flynn, MD
Program Chair and
President Elect to the
RMUS

Dear Colleagues,

Welcome to the Rocky Mountain Urological Society 2017 Annual Spring Meeting. We are very excited to see everyone. We have brought together a number of speakers, including two outside the RMUS: Drs. Robert Uzzo and Andrew Peterson.

Dr. Uzzo is leading the portion of the program dedicated to kidney cancer. Dr. Uzzo is the professor and chairman of the Department of Surgery, Fox Chase Cancer Center – Temple University Health System. He will give three talks: “Active Surveillance of Urologic Tumors – The Turtle in the Room,” “Managing RCC Risk – NSS in Patients with T1bT2 Renal Tumors,” and “Surgical Management of Advanced RCC – The Tale of Two Modalities.” Dr. Uzzo is an internationally recognized expert in kidney cancer, and we are fortunate to have him enlighten us on these controversial issues.

Dr. Peterson is leading the portion of the program dedicated to the new and exciting area of genitourinary cancer survivorship. Dr. Peterson is Duke University director of the urology residency program, director of the Reconstructive Urology and Genitourinary Cancer Survivorship Fellowship, and professor of surgery. Dr. Peterson will also give three talks: “Genitourinary Cancer Survivorship: The Role of the Urologist,” “Contemporary Options for Urinary Incontinence in the Prostate Cancer Survivor,” and “Long-term Complications of Radiation Therapy in Survivors of Prostate Cancer.” Dr. Peterson is the founder of this new subspecialty area; he has received funding, trained fellows, and has received recognition from the NIDDK in GU cancer survivorship.

We are excited to have robust multidisciplinary panel discussions with local experts in both kidney cancer and GU cancer survivorship to complement our visiting professors’ lectures. We are also having a talk on “Robotics and Laparoscopic Approaches to Kidney Cancer.” Once again, we are having University of Colorado and University of New Mexico residents present their research in an expanded poster section. Finally, new this year is the always popular and entertaining Resident’s Quiz Bowl.

We are excited to see many new and old friends in Denver for the RMUS meeting.

Sincerely,

Scott Jennings, MD
RMUS President

Brian J. Flynn, MD
Program Chair and President Elect to the RMUS

2016 - 2017 Board Of Directors

President

Scott B. Jennings, MD
1633 Medical Center Point
Colorado Springs, CO 80907
(719) 576-4744

President-Elect

Brian J. Flynn, MD
University of Colorado Denver
Division of Urology,
Room L15-5602
12631 E. 17th Ave., Box C319
Aurora, CO 80045
(720) 848-1855

Secretary/Treasurer

Sean P. Manion, MD
1925 Mountain View Ave.
Longmont, CO 80501
(303) 776-1234

Immediate Past President

Ali M. Sarram, MD
Advanced Urology, PC
11960 Lioness Way, Suite 210
Parker, CO 80134
(303) 695-6106

Legislative Representative

David L. Sobel, MD, JD
Urology Associates, PC
799 E. Hampden Ave.,
Suite 430
Englewood, CO 80113
(303) 733-8848

Northern Representative

Benjamin P. Wisner, MD
UC Health Urology
2315 E. Harmony Rd.,
Suite 140
Fort Collins, CO 80528
(970) 484-6700

Program Director

Randall B. Meacham, MD
University of Colorado School
of Medicine
Division of Urology M/S C-319
12631 E. 17th Ave.
Aurora, CO 80045
(303) 724-2714

Southern Representative

Richard A. Walsh III, MD
Pikes Peak Urology
6071 E. Woodmen Rd.,
Suite 300
Colorado Springs, CO 80923
(719) 531-7007

Western Representative

Craig A. Peterson, MD
San Juan Urology, PC
904 S. 4th St.
Montrose, CO 81401
(970) 249-2291

Program Committee

Brian J. Flynn, MD (Chair)
Scott B. Jennings, MD
Sean P. Manion, MD
Randall B. Meacham, MD
Ali M. Sarram, MD

Headquarter Office

WJ Weiser & Associates, Inc.
1100 E. Woodfield Rd.,
Suite 350
Schaumburg, IL 60173
(847) 517-7225

Executive Director

Wendy J. Weiser

Associate Director

Danielle Carrier



Rocky
Mountain
Urological
Society, Inc.

**2017 Annual Spring Meeting
April 7 – 8, 2017**

Welcome Message	1
Board of Directors.....	1
Educational Needs & Objectives	3
Accreditation Statement	4
Program Schedule.....	5
Invited Faculty	8
Faculty Biosketches.....	9
Resident Posters	11
Exhibit Guide	Appendix
Exhibit Hall Floor Plan	A1
Industry Satellite Symposium Events	A2
Industry Support	Back Cover

General Meeting Information

Registration/Information Desk Hours

Location: Ballroom Foyer

Friday, April 7, 2017

12:30 p.m. – 7:30 p.m.

Saturday, April 8, 2017

7:00 a.m. – 2:30 p.m.

Welcome Reception

Location: Arapahoe & Belleview

Friday, April 7, 2017

6:00 p.m. – 7:45 p.m.

Exhibit Hall Hours

Location: Arapahoe & Belleview

Friday, April 7, 2017

3:00 p.m. – 7:45 p.m.

Saturday, April 8, 2017

7:30 a.m. – 11:00 a.m.

Educational Needs

Kidney Cancer:

Kidney cancer is common in industrialized countries. It is the eighth most common type of cancer in the United States. This disease is associated with significant morbidity and death. Renal Cell Carcinoma is by far the most common type of kidney cancer in the United States. Kidney cancers are classified by size, vascular involvement, and metastases to surrounding organs.

There is significant variation in workup and treatment of kidney cancer across the country. Technology is rapidly changing, with introduction of numerous new medical, minimally invasive, and surgical options over the past few years. Given the significant role that community urologists play in diagnosis and treatment of kidney cancer, it is felt that a comprehensive update on diagnosis, workup, and treatment of kidney cancer is needed at this meeting.

Patients with high-risk kidney cancer present a unique challenge to the practicing urologist. The opportunity to preserve a patient's kidney must carefully be weighed against the risk of progression. In this session, the speakers will discuss the role of immunotherapy and chemotherapy in the management of kidney cancer and the risks of progression in these patients. In addition, the speaker will review the role of nephron sparing surgery.

There has been a fair bit of debate recently regarding the optimal surgical approach for patients with kidney cancer. However, in this session, the speaker will review the available

data for open, laparoscopic, and robotic nephrectomy and partial nephrectomy and make the case that patient selection is the critical component on which approach to choose. Nephron sparing surgery (SS) in patients with T1 and T2 is becoming more commonly utilized even in patients without obvious indications for NSS. Urologists need to understand the current trends and indications for NSS.

Robotic and Laparoscopic Surgery:

Robotic-assisted laparoscopic surgery is a minimally invasive way to perform abdominal and pelvic surgery. The Food and Drug Administration approved robotic surgery with the da Vinci Surgical System in 2000. The technique has been rapidly adopted by hospitals in the United States and Europe for use in the treatment of a wide range of conditions. The most widely used clinical robotic surgical system includes a camera arm and mechanical arms with surgical instruments attached to them. The surgeon controls the arms while seated at a computer console near the operating table. The console gives the surgeon a high definition, magnified, 3D view of the surgical site. The surgeon leads other team members who assist during the operation.

It is important that urologists specify and formulate the technical aspects and key procedural steps to optimize surgical outcomes. The speaker will give the audience the technical pearls to improve patient care and outcomes.

Prostate Cancer Therapy Complications:

Prostate cancer survivorship is a term that refers to the management of cancer treatment

related complications and improving HRQOL life for cancer survivors. Urinary incontinence and urethral stricture are the most common complications seen after prostate cancer therapy.

Urologists are frequently called upon to educate, diagnose, and treat men with urinary incontinence. New therapies for men with stress urinary incontinence include the male sling. It is important the urologist understands the role of the male sling versus the gold-standard artificial urinary sphincter (AUS). The outcome data on the male sling is conflicting. It is felt that a thorough discussion of this subject is much needed at this year's meeting. The speaker will give the audience technical pearls to improve continence outcomes following male sling and AUS surgery. The speaker will give the audience technical pearls to improve continence outcomes following penile prosthesis.

Health Policy and Medico-legal Concerns for Urologists:

As part of the rapidly changing health care delivery system in this country, payers both private and public systems are evolving to care for patients. Different systems use different models to care for patients and provide quality of care delivered by physicians. In the socioeconomic hour at this year's meeting, we will explore the changes in practice that impact physicians. We will also provide information on what happens when a patient files a complaint against a urologist and how the provider may respond, including the role of arbitration and settlement.

Educational Objectives

At the conclusion of the RMUS 2017 Annual Spring Meeting, attendees should be able to:

1. Identify the frequency of overtreatment of urologic tumors.
2. Identify treatment strategies to avoid overtreatment including triggers for intervention in the case of small renal masses.
3. Identify the risk factors for kidney cancer.
4. Describe when to perform nephron sparing in patients with T1 and T2 kidney cancer.
5. Identify appropriate risk trade-offs for complex partial nephrectomies in T1b and T2 renal tumors.
6. Identify opportunities to improve clinical outcomes when performing complex partial nephrectomies for T1b and T2 renal tumors.
7. Identify when nephrectomy is indicated.
8. Identify indications for adrenalectomy, lymphadenectomy, and cytoreductive nephrectomy in patients with locally advanced RCC.
9. Explain the distinct mechanisms of action for new systemic therapies for stage IV renal cancer and their potential role in adjuvant therapy.
10. Identify when caval thrombectomy is indicated.
11. Identify when immunotherapy for kidney cancer is indicated.
12. Identify when chemotherapy for kidney cancer is indicated.
13. Describe the role of interferon in the management of high-grade kidney cancers.
14. Report the risk factors for kidney cancer progression.
15. Demonstrate how to manage side effects of immunotherapy, and illustrate what to do when patients can't tolerate this therapy.
16. Analyze when to perform an open nephrectomy and when to perform Robotic or Laparoscopic nephrectomy.
17. Create factors that are important for patient selection for various approaches the nephrectomy.
18. Formulate the role of radiation therapy and chemotherapy in the treatment of kidney cancer.
19. Determine how to place trocars and dock the robot for robotic surgery, optimize patient positioning in robotic surgery.
20. Explain how to improve surgical techniques in robotic and laparoscopic kidney surgery.
21. Describe the role of the urologist in prostate cancer survivorship.
22. Explain the definition and magnitude of impact survivorship has in the United States today.
23. Recognize and diagnose side effects and complications from various forms of treatment for malignancies that may affect the genitourinary tract.
24. Implement a multidisciplinary approach towards the care of the cancer survivor.
25. Recognize that post prostatectomy treatment incontinence is common.
26. Recognize that post prostatectomy treatment incontinence has significant impact on quality of life.
27. Counsel patients regarding treatment options for post prostatectomy incontinence and the indications for those options including behavioral, medical, and surgical.
28. Describe surgical techniques for male sling.
29. Describe the surgical technique for artificial urinary sphincter (AUS).
30. Describe how to size the AUS.
31. Explain procedure selection for male incontinence surgery.
32. Explain the various complications that can arise immediately and in the long term from radiation to the lower genitourinary tract including fistula, stricture, voiding dysfunction, and incontinence.
33. Treat and longitudinally follow patients who have complications from radiation therapy including surgical, medical, and long-term follow-up.
34. Integrate surgical options for patients with lower genitourinary and upper genitourinary tract complications from radiation therapy into practice.
35. Describe the management of vesico-urethra anastomotic urethral stricture following radical prostatectomy.
36. Describe the management of bulbomembranous urethral stricture (BMUS) after brachytherapy.
37. Explain the incidence and severity of radiation complications in the lower urinary tract.
38. Describe how value based purchasing affects the business of medicine.
39. Explain the legal process if you are named in a patient complaint or lawsuit, arbitration, and/or settlement in a medical malpractice claim.

CONTINUING MEDICAL EDUCATION CREDIT INFORMATION

ACCREDITATION

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Surgeons and the Rocky Mountain Urological Society. The American College of Surgeons is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA CATEGORY 1 CREDITS™

The American College of Surgeons designates this live activity for a maximum of **9.75 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



AMERICAN COLLEGE OF SURGEONS

*Inspiring Quality:
Highest Standards, Better Outcomes*

100+ years



AMERICAN COLLEGE OF SURGEONS
DIVISION OF EDUCATION

*Accredited with Commendation by the
Accreditation Council for Continuing Medical Education*

Nurses and other healthcare professionals will receive a Certificate of Attendance. For information on the applicability and acceptance of Certificates of Attendance for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.

General Disclaimer

The statements and opinions contained in this program are solely those of the individual authors and contributors and not of the Rocky Mountain Urological Society. The appearance of the advertisements is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. The content of this publication may contain discussion of off-label uses of some of the agents mentioned. Please consult the prescribing information for full disclosure of approved uses. The Rocky Mountain Urological Society disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the abstracts or advertisements.

Special Assistance

We encourage participation by all individuals. If you have a disability, advance notification of any special needs will help us better serve you. Call (847) 517-7225 if you require special assistance to fully participate in the meeting.

Disclosure Report

In compliance with the ACCME Accreditation Criteria, the American College of Surgeons, as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. All reported conflicts are managed by a designated official to ensure a bias-free presentation.

RMUS 2017 Annual Spring Meeting

April 7 - 8, 2017

All sessions will be located in the **Colorado Room** unless otherwise noted.
Speakers and times are subject to change.

FRIDAY, APRIL 7, 2017

OVERVIEW

12:30 p.m. - 7:30 p.m. **Registration/Information Desk Open**
Location: Ballroom Foyer

3:00 p.m. - 7:45 p.m. **Exhibit Hall Open**
Location: Arapahoe & Belleview

6:00 p.m. - 7:45 p.m. **Welcome Reception with Exhibitors**
Location: Arapahoe & Belleview

GENERAL SESSION

1:00 p.m. - 1:05 p.m. **Welcome and Announcements**
President: Scott B. Jennings, MD
Colorado Springs, CO

1:05 p.m. - 1:45 p.m. **Active Surveillance of Urologic Tumors - The Turtle in the Room**
Speaker: Robert G. Uzzo, MD
Fox Chase Cancer Center
Philadelphia, PA

1:45 p.m. - 2:15 p.m. **Chemotherapy and Immunotherapy for Kidney Cancer**
Speaker: Maurice Markus, MD PhD
Rocky Mountain Cancer Center
Colorado Springs, CO

2:15 p.m. - 3:00 p.m. **Managing RCC Risk - NSS in Patients with T1bT2 Renal Tumors**
Speaker: Robert G. Uzzo, MD
Fox Chase Cancer Center
Philadelphia, PA

3:00 p.m. - 3:30 p.m. **Break with Exhibitors**
Location: Arapahoe & Belleview

3:30 p.m. - 4:15 p.m. **Surgical Management of Advanced RCC - The Tale of Two Modalities**
Speaker: Robert G. Uzzo, MD
Fox Chase Cancer Center
Philadelphia, PA

4:15 p.m. - 5:15 p.m. **Kidney Cancer Panel Discussion and Case Presentation**
Moderator: Nicholas Cost, MD
University of Colorado Anschutz Medical Campus
Denver, CO
Panelists: Maurice Markus, MD PhD
Rocky Mountain Cancer Center
Colorado Springs, CO
Paul Maroni, MD
University of Colorado Health Science Center
Aurora, CO
Ali M. Sarram, MD
Advanced Urology, PC
Parker, CO
Robert G. Uzzo, MD
Fox Chase Cancer Center
Philadelphia, PA

5:15 p.m. - 6:00 p.m.

RMUS Resident Quiz Bowl

Moderator: Julie M. Riley, MD
University of New Mexico
Albuquerque, NM

Judges: Sean P. Manion, MD
Longmont, CO
Andrew C. Peterson, MD, FACS, Professor of Surgery
Duke University Medical Center
Durham, NC

6:00 p.m.

Closing Remarks

SATURDAY, APRIL 8, 2017

OVERVIEW

7:00 a.m. - 2:30 p.m.

Registration/Information Desk Open

Location: Ballroom Foyer

7:30 a.m. - 11:00 a.m.

Exhibit Hall Open

Location: Arapahoe & Belleview

GENERAL SESSION

7:00 a.m. - 8:00 a.m.

Industry Satellite Symposium Breakfast

Location: Centennial

8:00 a.m. - 8:05 a.m.

Introduction

President: Scott B. Jennings, MD
Colorado Springs, CO

8:05 a.m. - 8:45 a.m.

Genitourinary Cancer Survivorship: The Role of the Urologist

Speaker: Andrew C. Peterson, MD, FACS, Professor of Surgery
Duke University Medical Center
Durham, NC

8:45 a.m. - 9:40 a.m.

Moderated Poster Session

Moderators: Frances M. Alba, MD
University of New Mexico
Albuquerque, NM
Shandra S. Wilson, MD
University of Colorado Health Science Center
Aurora, CO

9:40 a.m. - 10:20 a.m.

Contemporary Options for Urinary Incontinence in the Prostate Cancer Survivor

Speaker: Andrew C. Peterson, MD, FACS, Professor of Surgery
Duke University Medical Center
Durham, NC

10:20 a.m. - 10:40 a.m.

Break in the Exhibit Hall

Location: Arapaho & Belleview

10:40 a.m. - 11:10 a.m.

Even When You Do Everything Right...Responding to Patient Complaints

Speaker: Jeffrey L. Varnell, MD
Aurora, CO
COPIC Talk

11:10 a.m. - 11:45 a.m.

What Drives Outcomes in RALP

Speakers: Granville L. Lloyd, MD
Denver, CO
Paul Maroni, MD
University of Colorado Health Science Center
Aurora, CO

11:45 a.m. - 12:15 p.m.

Tips and Tricks for Robotic Renal Surgery

Speaker: Marklyn J. Jones, MD
The Urology Center of Colorado
Denver, CO

12:15 p.m. - 1:15 p.m.

Industry Satellite Symposium Lunch

Location: Centennial

1:15 p.m. - 1:45 p.m.

Long-term Complications of Radiation Therapy in Survivors of Prostate Cancer

Speaker: Andrew C. Peterson, MD, FACS, Professor of Surgery
Duke University Medical Center
Durham, NC

1:45 p.m. - 2:45 p.m.

Prostate Cancer Survivorship Panel Discussion and Case Presentation

Moderator: Brian J. Flynn, MD
University of Colorado Denver
Aurora, CO

Panelists: Ty T. Higuchi, MD, PhD
University of Colorado School of Medicine
Aurora, CO

Andrew C. Peterson, MD, FACS, Professor of Surgery
Duke University Medical Center
Durham, NC

David L. Sobel, MD, JD
Urology Associates, PC
Englewood, CO

2:45 p.m. - 3:00 p.m.

Annual Business Meeting

President: Scott B. Jennings, MD
Colorado Springs, CO

3:00 p.m.

Adjourn**Disclaimer Statement**

Statements, opinions, and results of studies contained in the program are those of the presenters/authors and do not reflect the policy or position of the Rocky Mountain Urological Society (RMUS) nor does the RMUS provide any warranty as to their accuracy or reliability.

Copyright Notice

Individuals may print out single copies of abstracts or slides contained in this publication for personal, non-commercial use without obtaining permission from the author or the RMUS. Permission from both the RMUS and the author must be obtained when making multiple copies for personal or educational use, for reproduction for advertising or promotional purposes, for creating new collective works, for resale, or for all other uses.

Filming/Photography Statement

No attendee/visitor at the RMUS 2017 Annual Spring Meeting may record, film, tape, photograph, interview, or use any other such media during any presentation, display, or exhibit without the express, advance approval of the RMUS Executive Director. This policy applies to all RMUS members, non-members, guests, and exhibitors, as well as members of the print, online, or broadcast media.

The Rocky Mountain Urological Society welcome Dr. Andrew C. Peterson and Dr. Robert G. Uzzo to the 2017 Annual Spring Meeting. These accomplished urologists join us from outside the RMUS. We are pleased to have them, and we are excited to hear their numerous presentations.



Andrew C. Peterson, MD received his medical degree from Dartmouth Medical School in 1995. He completed his surgery internship at Madigan Army Medical Center in 1996. He completed his urology residency at Madigan in 2002 and subsequently completed a fellowship in reconstructive urology at Duke University in 2003.

He then returned to Madigan Army Medical Center where he served as the chief of reconstructive urology and the director of the urology residency. Dr. Peterson also served as the chairman of the institutional animal care and use committee (IACUC) and was on the institutional review board (IRB), the American Urologic Association guidelines committee, as well as the program and essay committee for the Western Section of the American Urologic Association.

Dr. Peterson joined the faculty at Duke in 2010 where he serves as the vice chief of medical operations and urology residency program director. In addition to these duties, he also directs the "Reconstructive Urology and Genitourinary Cancer Survivorship Fellowship." His research and clinical interests include improving the care of cancer survivors and the prevention of genitourinary side effects from various medical, surgical, and radiation therapies for cancer. He has published more than 70 publications and abstracts in the peer reviewed literature, in addition to eight book chapters. He currently serves on the review panel of multiple peer reviewed journals. He serves on the board of directors for the Society for Genitourinary Reconstructive Surgeons and the Society for Government Service Urologists.

During his time in the military, Dr. Peterson achieved the rank of Colonel and retired from the Army Reserves in 2014. He is a graduate of the advanced course for medical officers, the Command and General Staff College, and has been awarded the Expert Field Medical Badge, the Meritorious Service Medal with three oak leaf clusters, the Bronze Star, and the Legion of Merit.

Dr. Peterson will present:

1. *Genitourinary Cancer Survivorship: The Role of the Urologist*
2. *Contemporary Options for Urinary Incontinence in the Prostate Cancer Survivor*
3. *Long-term Complications of Radiation Therapy in Survivors of Prostate Cancer*



Robert G. Uzzo, MD graduated summa cum laude and valedictorian from Union College where he was a New York State Finalist for the Rhodes Scholarship. He then attended Cornell University Medical College and completed general surgical training followed by urologic surgical training at New York Hospital – Cornell Medical Center and Memorial Sloan-Kettering Cancer Center.

He was an American Foundation for Urological Diseases Scholar in urological oncology and completed both oncological and renal transplantation fellowships at the Cleveland Clinic.

Dr. Uzzo is currently the deputy chief clinical officer, professor, and chairman of surgery at Temple University's Fox Chase Cancer Center. He is also the Chairman of the Fox Chase/Einstein Urologic Institute. He maintains an active, funded laboratory investigating kidney and prostate cancer. His clinical interests include minimally invasive urological oncology and renal malignancies. He has authored over 350 peer-reviewed articles and chapters in urologic oncology.

Dr. Uzzo will present:

1. *Active Surveillance of Urologic Tumors - The Turtle in the Room*
2. *Managing RCC Risk - NSS in Patients with T1bT2 Renal Tumors*
3. *Surgical Management of Advanced RCC - The Tale of Two Modalities*



Frances M. Alba, MD is a board certified urologist at the University of New Mexico. She is an assistant professor at UNM and currently practices at UNM Hospital, UNM Cancer Center, and serves as the director of urology at Sandoval Regional Medical Center. She received her medical degree from the University of New Mexico School of Medicine. Dr. Alba completed residency training at University of Texas Houston

Medical School and MD Anderson Cancer Center in Houston, Texas. Her practice interests encompass all aspects of genitourinary oncology, including bladder, kidney, prostate, and testis cancer.



Nicolas Cost, MD currently serves as an assistant professor in the department of surgery, division of urology at the University of Colorado – School of Medicine. He concentrates his clinical and research efforts in the areas of urologic oncology and pediatric urology. Within this realm, Dr. Cost focuses on testicular cancer and kidney cancer, specifically in the pediatric, adolescent and young adult population, and those with hereditary renal malignancy syndromes.

He did his undergraduate training at Vanderbilt University in Nashville, Tennessee, and then went on to Emory University in Atlanta, Georgia for medical school. Subsequently, he did his urology residency at the University of Texas Southwestern Medical Center in Dallas, Texas. Following this, Dr. Cost stayed in Dallas and completed fellowship training in urologic oncology at the University of Texas Southwestern Medical Center. Next, he moved on to Cincinnati, Ohio, for a pediatric urology fellowship at Cincinnati Children's Hospital Medical Center. He began his first faculty appointment in the fall of 2013 at the University of Colorado School of Medicine and practices between the University of Colorado Cancer Center and the Children's Hospital Colorado, both of which are on the Anschutz Medical Campus of the University of Colorado-Denver.

Dr. Cost's research is currently focused in multi-institutional research on surgical quality in the care of adolescents and young adults with renal tumors. Outside of his clinical and academic work locally, he is proud to serve as a central surgical reviewer for the renal tumor committee of the Children's Oncology Group, which extends to his role as study vice chair for an NCI study on patients with advanced translocation renal cell carcinoma.



Brian J. Flynn, MD is the co-director of FPMRS at the University of Colorado Hospital. He is a professor of surgery/urology and fellowship director of reconstructive urology at the University of Colorado Denver. Dr. Flynn received his BS in Electrical Engineering from the University of Rochester and Doctorate of Medicine from Temple University. He completed a residency in urology at Geisinger Medical Center and his fellowship in FPMRS and reconstructive urology at Duke University.

His primary areas of interest are male and female pelvic reconstructive surgery and female pelvic medicine. He is a national leader in the use of minimally invasive surgical techniques for the treatment of urinary incontinence and pelvic floor repairs in women. He has written updates for the AUA and has provided postgraduate instruction on the surgical management of post-prostatectomy incontinence, mesh removal, and genitourinary fistula surgery. He has authored numerous clinical papers, surgical videos, and textbook chapters. He has presented internationally on various topics including male and female urinary incontinence, pelvic organ prolapse, urinary diversion, urethral reconstruction, and urethral stricture disease.



Ty T. Higuchi, MD is a Colorado native who grew up in Colorado Springs and then completed his undergraduate and graduate degrees at Colorado State University. He then attended medical school at the University of Nebraska Medical Center and completed his urology residency at the Mayo Clinic in Rochester, Minnesota. He then went on to complete a fellowship in male reconstructive and transitional

urology at the Cleveland Clinic. He joined the faculty at the University of Colorado in 2012 and holds appointments at the University of Colorado Hospital and Children's Hospital Colorado. Dr. Higuchi's clinical interests include general urology, male urethral strictures, rectourethral fistula, male urinary incontinence, Peyronie's disease, medical and surgical erectile dysfunction, neurogenic bladder, urethral strictures, and radiation cystitis. He has a unique interest in congenitalism and spends a portion of his time at Children's Hospital Colorado caring for adolescent and young adults with congenital bladder anomalies who need lifelong surveillance and urologic care.



Scott B. Jennings, MD earned his BA in biology from Whitman College in 1982 and his medical degree in 1987 from the University of New Mexico School of Medicine in Albuquerque. He went on to do an internship and a residency in general surgery and a residency in urologic surgery at the University of Kansas Medical Center. He had a fellowship in urologic oncology at the National Cancer Institute from 1993 to

1995. He became an instructor of surgery at the Medical College of Pennsylvania in 1995 before moving into private practice in 1997. Since 2000, he has worked at Colorado Springs Health Partners in Colorado Springs. He is married with two children.



Marklyn (Mark) Jones, MD earned a Bachelor of Science in biology, cum laude, and his medical doctorate from Creighton University. During medical school, Dr. Jones was awarded with induction into the Alpha Omega Alpha (AOA) Honor Medical Society. He completed his internship and residency training at the University of Minnesota. Dr. Jones also completed his fellowship training in advanced laparoscopy,

robotic surgery, and urologic oncology at the University of Minnesota. After completing his fellowship, he joined The Urology Center of Colorado (TUCC) in Denver, Colorado.

Dr. Jones dedicates his entire practice to robotic surgery of all types using the da Vinci robot. He has performed hundreds of minimally invasive surgeries for TUCC patients since August 2007. He serves as the primary laparoscopic nephrectomy donor surgeon for Presbyterian/St. Luke's Kidney Transplant Center. He is also the medical director of robotic surgery at Porter Adventist Hospital. Dr. Jones is a member of several professional organizations including the American Urological Association, Endourologic Society of America, Rocky Mountain Urological Society, Denver Medical Society, and the Colorado Medical Society. He has authored several peer-reviewed journal articles and has presented on several occasions at the annual meeting of the American Urological Association. Dr. Jones is board certified by the American Board of Urology.



Granville Lloyd, MD grew up in Longmont, Colorado, and graduated from the University of Colorado Boulder with degrees in molecular biology and psychology. He attended medical school at the Dartmouth – Brown program, trained in urology at Northwestern University in Chicago, and ultimately completed a fellowship in robotic surgery at the University of Rochester.

After four years as a member of the core faculty at the University of Wisconsin, he returned to Colorado as director of robotic surgery at the Denver VA hospital in 2016. His interests include both patient and surgeon factors, as they apply to robotic and laparoscopic surgery. He is a devoted skier, mountain biker, and bar-league hockey player.



Sean Manion, MD graduated from St. Thomas Academy in St. Paul, Minnesota in 1983. He went on to receive a BS from Notre Dame University in Indiana prior to attending medical school. Dr. Manion received his MD from Loyola University Medical Center in Chicago in 1991. He completed residencies in both general surgery and urology at the Loyola University Medical Center in Maywood, Illinois. Dr. Manion

is board certified in urology. He is a member of the American Urology Association and a diplomat of the American Board of Urology. He was the chief of urology at Reynolds Army Community Hospital in Ft. Sill, Oklahoma, before he joined Longmont Clinic in September 2000.



Maurice Markus, MD is a medical oncologist with the Rocky Mountain Cancer Centers, Colorado Springs. He earned his medical degree from Weill Medical College of Cornell University, and then completed a residency and fellowship at New York Presbyterian Hospital and Duke University Medical Center, respectively. He is board certified in medical oncology, hematology, and internal medicine.



Paul Maroni, MD is an associate professor of surgery in the division of urology at the University of Colorado Anschutz Medical Campus. He is operations director of the Urologic Oncology Clinic. He completed urology residency training at the University of Colorado Health Sciences Center and then finished a urologic oncology fellowship at Indiana University in 2007.

Dr. Maroni's clinical interests include open and minimally invasive surgical management of prostate, kidney, or testis cancer. Research and academic interests include quality improvement in surgery, effective educational techniques for surgical learners, and quality of life assessment in cancer survivors.



Randall B. Meacham, MD is professor and chief of the division of urology and urology residency program director at the University of Colorado School of Medicine. He received his medical degree from Baylor College of Medicine where he also completed his urology residency and a fellowship in male reproductive medicine and surgery. Dr. Meacham's primary area of clinical and academic activity is the evaluation and

treatment of male infertility, with a focus on microsurgical reconstruction. Dr. Meacham currently serves as chair of the urology residency review committee of the ACGME and on the board of directors of the American Urological Association.



Julie Riley, MD is an assistant professor at the University of New Mexico in Albuquerque, New Mexico. She is currently the director of endourology and stone disease as well as the director of urologic research and medical director of the urology clinic. She completed a two-year fellowship at the University of Pittsburgh in endourology and robotics/laparoscopy and a urology residency at the University of Missouri – Columbia. She obtained her MD from St. Louis University School of Medicine with a distinction in community service. Her interests include metabolic and surgical stone disease as well as urethral reconstruction, renal transplantation, and robotic partial nephrectomy.



Ali M. Sarram, MD received his undergraduate and medical education at the University of Washington in Seattle. He then completed an internship and residency in general surgery and urology at the University of Colorado. Dr. Sarram received a fellowship in minimally invasive surgery and renal transplantation at the Virginia Mason Medical Center in Seattle, after which he joined Advanced Urology. He has been practicing

urology in Colorado since 2002, focusing his efforts on minimally invasive laparoscopic and da Vinci robotic surgery.



David L. Sobel, MD, JD earned his medical degree from the University of Illinois at Chicago Medical School, then completed his urologic training at Rush University Medical Center in Chicago in 2005. He joined Urology Associates in February 2009. Dr. Sobel is board certified by the American Board of Urology in adult and pediatric urology and is a member of the American Urological Society and the Sexual

Medicine Society of North America. He is also a founding member of the Denver Sexual Medicine Alliance.

Prior to his medical career, Dr. Sobel spent several years as a corporate attorney at the law firm of Paul, Weiss, Rifkind, Wharton & Garrison. He earned a JD from the University of Michigan Law School and completed his undergraduate studies at the University of Michigan with a concentration in religion. Dr. Sobel is also the founder of Emmi Solutions, LLC, a company that creates interactive, web-based programs designed to explain complex information to patients and to better prepare them for upcoming surgery.



Jeffrey L. Varnell, MD grew up in Denver, Colorado. He graduated with a Bachelor of Science in biology from Stanford University in 1972 and received his Doctor of Medicine at the University of Colorado in 1976. He served as chief of staff and chief of surgery at The Medical Center of Aurora in the past and currently works with COPIC Insurance as a physician risk manager. Dr. Varnell's clinical focus is thyroid biopsies performed in the office.



Shandra S. Wilson, MD is an associate professor at the University of Colorado Denver – Department of Surgery/Division of Urology. She completed a fellowship at the University of Colorado in urologic oncology in 2004. Dr. Wilson finished her urology residency training at the University of Southern California Los Angeles and the University of Mississippi Jackson. She also completed general surgery residency training at West Virginia University Morgantown.

Alek Blubaum, MD
University of Colorado

Alonso Carrasco Jr., MD
University of Colorado

Salvatore Catarinicchia, MD
University of Colorado

Clayton Davis
Rocky Vista University College of Osteopathic Medicine

Rodrigo Donalisio da Silva, MD
University of Colorado

S. Clint McFerren, MD
University of New Mexico

Lisa Parrillo, MD
University of Colorado

Megan Perez
University of Colorado

Amanda F. Saltzman, MD
University of Colorado

Jason C. Warncke, MD
University of Colorado

Bradley Webster, MD
University of New Mexico

Cole A. Wiedel, MD
University of Colorado


Bryan Wilson, MD
University of New Mexico



Rocky Mountain Urological Society
2017 Annual Spring Meeting
April 7 - 8, 2017
Embassy Suites Denver Tech Center
Centennial, Colorado

Rocky
Mountain
Urological
Society

EXHIBIT GUIDE



Company Name	Booth #	Company Name	Booth #
AbbVie	11	GenomeDx Biosciences Inc.	4
Allergan, Inc.	21	Genomic Health	12
Ambry Genetics	14	Janssen Biotech	15
Astellas Pharma US, Inc.	2	KARL STORZ	7
Astellas/Medivation, a Pfizer Company	16	Lumenis, Inc.	3
Boston Scientific Corporation	17,18	MDxHealth	9
Cogentix Medical	10	Myriad Genetic Laboratories, Inc.	19
Cook Medical	1	NeoTract, Inc.	13
Dendreon	8	Retrophin	6
Exelixis Inc	22	Richard Wolf Medical Instruments, Corp.	20
Ferring Pharmaceuticals	5	Wave Form Systems, Inc.	23

SATURDAY, APRIL 8, 2017

7:00 a.m. - 8:00 p.m. Industry Satellite Symposium Breakfast

Sponsored by: KOL Consortium

Location: Centennial

“Breakthroughs with Prostate Cancer Markers and Risk Stratification in Prostate Cancer: Genetics and Genomics”

E. David Crawford, MD, PhD

Professor of Urology/Surgery/Radiation Oncology

University of Colorado, Denver, CO

12:15 p.m. - 1:15 p.m. Industry Satellite Symposium Lunch

Sponsored by: Astellas/Medivation, a Pfizer Company

Location: Centennial

“Elevate Care in Advanced Prostate Cancer”

E. David Crawford, MD, PhD

Professor of Urology/Surgery/Radiation Oncology

University of Colorado, Denver, CO

Thank You To Our 2017 Promotional Partner

(alphabetical as of 3/27/2017)

Platinum Level Partner



Thank You To Our 2017 Exhibitors

AbbVie
Allergan, Inc.
Ambry Genetics
Astellas Pharma US, Inc.
Astellas/Medivation, a Pfizer Company
Boston Scientific Corporation
Cogentix Medical
Cook Medical
Dendreon
Exelixis Inc
Ferring Pharmaceuticals
GenomeDx Biosciences Inc.
Genomic Health
Janssen Biotech
KARL STORZ
Lumenis, Inc.
MDxHealth
Myriad Genetic Laboratories, Inc.
NeoTract, Inc.
Retrophin
Richard Wolf Medical Instruments, Corp.
Wave Form Systems, Inc.

Thank You To Our 2017 Contributors

Genomic Health
KOL Consortium LLC